Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT2Q6G1)

• DTT Name: Vascular endothelial growth factor receptor 1 (FLT-1) DTT Info
• UniProt ID: VGFR1_HUMAN
• Gene Name: FLT1

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tivozanib	DMUKC5L	Renal cell carcinoma	2C90	Approved	[1]

10 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[2]
Fruquintinib	DMHOSCQ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[3]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[4]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[5]
LY3012212	DMRVEHY	Arteriosclerosis	BD40	Phase 2	[6]
OCV-101	DMT9QI2	Pancreatic cancer	2C10	Phase 2	[7]
X-82	DMW1NKO	Age-related macular degeneration	9B75.0	Phase 2	[8]
OTSGC-A24	DMN0ZQ5	Colorectal cancer	2B91.Z	Phase 1/2	[9]
CEP-11981	DMYDTJ6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
EW-A-401	DM3VC6T	Peripheral vascular disease	BD4Z	Phase 1	[11]

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Angiozyme	DMBQLS5	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[12]
Telbermin	DMIDGZU	Diabetic foot ulcer	BD54	Discontinued in Phase 2	[13]

2 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AAL-993	DM35RFH	Discovery agent	N.A.	Investigative	[14]
SU-11652	DMGQXN7	Discovery agent	N.A.	Investigative	[15]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [2] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [3] Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
• [4] Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
• [5] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
• [6] Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. 2014 Apr;32(2):303-11.
• [7] Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.Cancer Sci.2013 Jan;104(1):98-104.
• [8] National Cancer Institute Drug Dictionary (drug id 695817).
• [9] J Clin Oncol 33, 2015 (suppl 3; abstr 65).
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8189).
• [11] DOI: http://dx.doi.org/10.1016/j.tips.2014.09.007
• [12] An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer.Cancer.2012 Sep 1;118(17):4098-104.
• [13] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
• [14] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [15] Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.